Table 2.

Clinical trials using post-transplant bendamustine in allogeneic HCT.

	N	Age	Donor Graft	Disease	Remission Status %	Regimen	Engraft %	aGvHD III-IV %	cGvHD %	NRM %	Relapse %	OS %	EFS %
Katsanis (Tucson, Arizona) 2016- NCT02996773 Phase I/Ib Dose-escalation of PT-BEN day +4 (20-60-90 mg/m2)/ de-escalation of PT-CY Day +3 CY	9 ongoing	9–42	Haplo BM	Leuk Lymph	33 CR1 22 CR2 22 >CR2 22 PR	MAC TBI-FLU or BU-FLU-MEL	100	0	0	0	29 @ 2yr	83 @ 2y	71 @ 2yr
Moiseev (St. Petersburg, Russia) 2016- NCT02799147 Phase I/II De-escalation of PT-BEN days +3, +4 (140-100-70mg/m2)	26 closed	20–56	MSD or MUD or Haplo PBSC	Leuk	RD	MAC BU-FLU	92	43 30 33	70	43	19	29 40 70 @ 1y	29 40 27 @ 1y
Khouri (Houston, Texas) 2019- NCT04022239 Phase I/II Day +4 BEN Dose-escalation of PT-BEN day +3/de-escalation of PT-CY	ongoing	18–65	Haplo or MMUD PBSC	Leuk Lymph	?	RIC FLU-MEL-TBI or FLU-BEN-TBI ± Ritux	-	-	-	-	-	-	-

BEN = bendamustine, CY = cyclophosphamide; Haplo = haploidentical, BM = bone marrow, MSD = matched sibling donor, MUD = matched unrelated donor, PBSC = peripheral blood stem cells, MMUD = mismatched unrelated donor, Leuk = leukemia, Lymph = lymphoma, CR = complete remission, PR = partial remission, RD = refractory disease; MAC = myeloablative conditioning, TBI = total body irradiation, FLU = fludarabine, BU = busulfan, MEL = melphalan, RIC = reduced intensity conditioning, Ritux = rituximab, Engraft = engraftment; aGvHD = acute graft versus host disease, cGvHD = chronic graft versus host disease, NRM = non-relapse mortality, OS = overall survival, EFS = event free survival; ? = unknown.